(Q34985117)

5 August 2017

1 reference

title

Immunoeffector and immunoregulatory activities of vasoactive intestinal peptide (English)

1 reference

5 August 2017

6

Edward J Goetzl

1 reference

5 August 2017

Julia K Voice

1

1 reference

5 August 2017

Glenn Dorsam

2

1 reference

5 August 2017

Robert C Chan

3

1 reference

5 August 2017

Carola Grinninger

4

1 reference

5 August 2017

Yvonne Kong

5

1 reference

5 August 2017

1 November 2002

1 reference

5 August 2017

1 reference

5 August 2017

109

1 reference

5 August 2017

1-3

1 reference

5 August 2017

199-208

1 reference

Vasoactive intestinal peptide mediation of development and functions of T lymphocytes.

5 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900182-9

7 January 2021

Vasoactive intestinal peptide (VIP) mRNA expression in rat T and B lymphocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900182-9

7 January 2021

The significance of vasoactive intestinal polypeptide (VIP) in immunomodulation

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900182-9

7 January 2021

Upregulation of neuropeptides and neuropeptide receptors in a murine model of immune inflammation in lung parenchyma

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900182-9

7 January 2021

Multiple neuropeptides in nerves supplying mammalian lymph nodes: messenger candidates for sensory and autonomic neuroimmunomodulation?

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900182-9

7 January 2021

Regulation of VIP production and secretion by murine lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900182-9

7 January 2021

Cutting edge: is vasoactive intestinal peptide a type 2 cytokine?

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900182-9

7 January 2021

Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900182-9

7 January 2021

Effect of vasoactive intestinal peptide (VIP) on cytokine production and expression of VIP receptors in thymocyte subsets.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900182-9

7 January 2021

Vasoactive intestinal peptide in thymus: synthesis, receptors and biological actions

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900182-9

7 January 2021

Differential expression of vasoactive intestinal peptide receptors 1 and 2 (VIP-R1 and VIP-R2) mRNA in murine lymphocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900182-9

7 January 2021

Allergic diathesis in transgenic mice with constitutive T cell expression of inducible vasoactive intestinal peptide receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900182-9

7 January 2021

Murine T-lymphocytes express vasoactive intestinal peptide receptor 1 (VIP-R1) mRNA.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900182-9

7 January 2021

Selective gene expression and activation-dependent regulation of vasoactive intestinal peptide receptor type 1 and type 2 in human T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900182-9

7 January 2021

VIP and PACAP enhance IL-6 release and mRNA levels in resting peritoneal macrophages: in vitro and in vivo studies.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900182-9

7 January 2021

VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages. Subsequent effect on IFNgamma synthesis by T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900182-9

7 January 2021

Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide modulate endotoxin-induced IL-6 production by murine peritoneal macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900182-9

7 January 2021

Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit expression of Fas ligand in activated T lymphocytes by regulating c-Myc, NF-kappa B, NF-AT, and early growth factors 2/3.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900182-9

7 January 2021

Mediators of communication and adaptation in the neuroendocrine and immune systems

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900182-9

7 January 2021

In vitro alteration of receptors for vasoactive intestinal peptide changes the in vivo localization of mouse T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900182-9

7 January 2021

Vasoactive intestinal peptide inhibits interleukin (IL)-2 and IL-4 production through different molecular mechanisms in T cells activated via the T cell receptor/CD3 complex

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900182-9

7 January 2021

Enhancement by vasoactive intestinal peptide of gamma-interferon production by antigen-stimulated type 1 helper T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900182-9

7 January 2021

Isotype-specific regulation of human lymphocyte production of immunoglobulins by sustained exposure to vasoactive intestinal peptide

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900182-9

7 January 2021

Vasoactive intestinal peptide induces S(alpha)/S(mu) switch circular DNA in human B cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900182-9

7 January 2021

Enhanced delayed-type hypersensitivity and diminished immediate-type hypersensitivity in mice lacking the inducible VPAC(2) receptor for vasoactive intestinal peptide.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900182-9

7 January 2021

Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit tumor necrosis factor alpha transcriptional activation by regulating nuclear factor-kB and cAMP response element-binding protein/c-Jun

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900182-9

7 January 2021

Vasoactive intestinal peptide receptor-1 (VPAC-1) is a novel gene target of the hemolymphopoietic transcription factor Ikaros

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900182-9

7 January 2021

Low level formation of potent catalytic IgG fragments mediated by disulfide bond instability

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900182-9

7 January 2021

Cleavage specificity of a proteolytic antibody light chain and effects of the heavy chain variable domain

1 reference

https://api.crossref.org/works/10.1016%2FS0167-0115%2802%2900182-9

7 January 2021

10.1016/S0167-0115(02)00182-9

Identifiers

DOI

1 reference

5 August 2017

1 reference